
ACR Annual Meeting: Compared with seven other biologics and a phosphodiesterase-4 inhibitor, the anti-IL-12/23 biologic ustekinumab was associated with a generally lower risk of serious infection requiring hospitalization in psoriasis or psoriatic arthritis patients, researchers reported on November 12 at the American College of Rheumatology annual meeting in Atlanta.



























